FAIR LAWN, NJ - (December 4, 2007) - Vyteris, Inc. (OTCBB: VYHN), manufacturer of LidoSite®, the first active transdermal patch approved by the U.S. Food and Drug Administration for the pain associated with blood draws (venipuncture), IV (intravenous) cannulations and laser ablation of superficial skin lesions, today announced the expected ass...

Dutton Associates initiates coverage of Vyteris (OTCBB:VYHN) with a Speculative Buy rating and a target price of $2.40. The 24-page report by Dutton senior analyst Richard West, CFA is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Reuters, Knobias, and other leading financial por...

Vyteris, Inc. (OTCBB: VYHN) kicked off the nationwide commercial availability of its LidoSite(R) transdermal patch with the deployment of a specialty sales and marketing team dedicated to the promotion and sale of LidoSite into targeted physician specialty offices, including rheumatologists, oncologists, and ...

Vyteris Inc. (OTCBB: VYHN) today announced the completion of a new private placement financing transaction in which it raised $12.7 million in cash, for net proceeds of $11.4 million after legal and transactions costs of $1.3 million. This follows another financing round last October 2006 for $23.1 million. ...

Vyteris Holdings (Nevada), Inc. (OTCBB: VYHN), today announced the completion of a series of financing transactions in which it raised more than $23.1 million, of which $20.1 million was in cash and $3.0 million in non-cash debt conversion, from October 2006 and ending April 15, 2007. "This success...

Vyteris Holdings (OTCBB: VYHN) today announced that it has entered into a letter of intent to acquire Lehigh Valley Technologies, Inc., (LVT) an Allentown, PA-based, growing specialty pharmaceutical company. Although both companies expect to work toward a closing in an expeditious manner, the transaction is s...

Vyteris, Inc. (OTCBB: VYHN.OB), makers of LidoSite(R), the first active drug delivery patch to receive marketing clearance from the U.S. Food and Drug Administration (FDA), today announced promotions of five current members of the executive team to more accurately reflect and focus th...